BMIPP imaging to assess functional outcome in patients with acute and chronic left ventricular dysfunction.

International journal of cardiac imaging Pub Date : 1999-02-01 DOI:10.1023/a:1006128116056

P R Franken, A S Hambÿe, F W De Geeter

{"title":"BMIPP imaging to assess functional outcome in patients with acute and chronic left ventricular dysfunction.","authors":"P R Franken, A S Hambÿe, F W De Geeter","doi":"10.1023/a:1006128116056","DOIUrl":null,"url":null,"abstract":"<p><p>Assessment of myocardial viability is an important clinical issue for patient management during the acute and chronic stages of myocardial infarction. BMIPP (15-(p-iodophenyl)-3-(R,S)-methyl pentadecanoic acid) is a free fatty acid analogue which is trapped in the myocardium, thus permitting for metabolic imaging with single photon emission computerized tomography (SPECT). Less BMIPP than flow tracers that may be observed in the areas of infarction, may reflect the metabolic shift from fatty acid to glucose utilization in ischaemic myocardium. In this sense, the combined imaging of BMIPP and a flow tracer with SPECT may provide similar and important information as fluoro-18 deoxyglucose (FDG) and positron emission tomography (PET) regarding the assessment of myocardial viability. The purpose of this article is to review the clinical impact of BMIPP in patients with acute and with chronic left ventricular dysfunction for the identification of jeopardized but viable myocardium and the prediction of the functional outcome.</p>","PeriodicalId":77179,"journal":{"name":"International journal of cardiac imaging","volume":"15 1","pages":"27-34"},"PeriodicalIF":0.0000,"publicationDate":"1999-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1023/a:1006128116056","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of cardiac imaging","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1023/a:1006128116056","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 5

Abstract

Assessment of myocardial viability is an important clinical issue for patient management during the acute and chronic stages of myocardial infarction. BMIPP (15-(p-iodophenyl)-3-(R,S)-methyl pentadecanoic acid) is a free fatty acid analogue which is trapped in the myocardium, thus permitting for metabolic imaging with single photon emission computerized tomography (SPECT). Less BMIPP than flow tracers that may be observed in the areas of infarction, may reflect the metabolic shift from fatty acid to glucose utilization in ischaemic myocardium. In this sense, the combined imaging of BMIPP and a flow tracer with SPECT may provide similar and important information as fluoro-18 deoxyglucose (FDG) and positron emission tomography (PET) regarding the assessment of myocardial viability. The purpose of this article is to review the clinical impact of BMIPP in patients with acute and with chronic left ventricular dysfunction for the identification of jeopardized but viable myocardium and the prediction of the functional outcome.

查看原文本刊更多论文

BMIPP成像评估急性和慢性左心室功能不全患者的功能结局。

心肌活力评估是急性和慢性心肌梗死患者管理的重要临床问题。BMIPP(15-(对碘苯基)-3-(R,S)-甲基五酸)是一种游离脂肪酸类似物，它被捕获在心肌中，因此可以用单光子发射计算机断层扫描(SPECT)进行代谢成像。在梗死区域观察到的BMIPP低于血流示踪剂，可能反映了缺血心肌从脂肪酸到葡萄糖利用的代谢转变。从这个意义上说，在评估心肌活力方面，BMIPP和血流示踪剂与SPECT的联合成像可能提供与氟-18脱氧葡萄糖(FDG)和正电子发射断层扫描(PET)相似的重要信息。本文的目的是回顾BMIPP在急性和慢性左心室功能不全患者中识别受损但存活的心肌和预测功能结局的临床影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International journal of cardiac imaging

自引率

0.00%

发文量